NASDAQ Composite ended the session with Arena Pharmaceuticals jumping 2.93% to $76.50 on Tuesday, after two successive sessions in a row of losses. NASDAQ Composite jumped 0.23% to $13,066.03, following last session’s downward trend on what was a somewhat positive trend exchanging session today.
Arena Pharmaceuticals today’s close was $76.50, 17.90% below its 52-week high of $90.19.
Arena Pharmaceuticals’s Sales
Arena Pharmaceuticals’s sales growth is a negative 81.3% for the ongoing quarter and 155.7% for the next. The company’s growth estimates for the present quarter is a negative 4.5% and positive 4.5% for the next.
Arena Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth declined by 98.5%, now sitting on 3.28M for the twelve trailing months.
Arena Pharmaceuticals’s last day, last week, and last month’s average volatility was a negative 3.79%, a negative 0.28%, and a positive 0.36%, respectively.
Arena Pharmaceuticals’s last day, last week, and last month’s high and low average amplitude percentage was 4.84%, 3.33%, and 3.38%, respectively.
Arena Pharmaceuticals’s Stock Yearly Top and Bottom Value
Arena Pharmaceuticals’s stock is valued at $76.50 at 16:26 EST, way below its 52-week high of $90.19 and way above its 52-week low of $32.95.
Arena Pharmaceuticals’s Moving Average
Arena Pharmaceuticals’s value is above its 50-day moving average of $71.61 and higher than its 200-day moving average of $70.89.